MedTrace Logo

Effectiveness Study of Short Course of Magnesium Sulfate for Severe Preeclamsia

NCT01408979 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 120

Last updated 2012-08-22

No results posted yet for this study

Summary

Magnesium sulfate is the ideal drug for seizures prophilaxis in preeclampsia. The ideal duration of this treatment after delivery is still to be established. The hypothesis is that in stable patients a shorter course of treatment is possible without prejudice to the mother.

Conditions

  • Severe Preeclampsia

Interventions

DRUG

Magnesium sulfate 12 hours

Magnesium sulfate, 1g/h, (10% solution), for 12 hours

DRUG

Magnesium sulfate 24 hours

Magnesium sulfate, 1g/h, (10% solution), for 24 hours

Sponsors & Collaborators

  • Instituto Materno Infantil Prof. Fernando Figueira

    lead OTHER

Principal Investigators

  • Melania M Amorim, MD; PhD · IMIP

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
11 Years
Max Age
50 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-08-31
Primary Completion
2011-12-31
Completion
2012-02-29

Countries

  • Brazil

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01408979 on ClinicalTrials.gov